Martijn van de Hel assisted academic hospitals Erasmus MC, LUMC, UMCG and GenomeScan in obtaining approval from the NZa and the ACM. The approval concerned the entry of UMCG as a new shareholder in GenomeScan.
GenomeScan is a laboratory that provides innovative DNA/RNA analyses for genetic laboratory research. GenomeScan provides its services both to third parties and the university hospitals. Already in 2019, the ACM and the NZa approved the entry of Erasmus MC as one of the shareholders - next to LUMC - in GenomeScan.
The entry of UMCG as a new shareholder in GenomeScan was approved by the ACM on May 25, 2022. The NZa approved the entry on April 21, 2022.
